uric acid has been researched along with Berger Disease in 56 studies
Uric Acid: An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.
uric acid : An oxopurine that is the final oxidation product of purine metabolism.
6-hydroxy-1H-purine-2,8(7H,9H)-dione : A tautomer of uric acid having oxo groups at C-2 and C-8 and a hydroxy group at C-6.
7,9-dihydro-1H-purine-2,6,8(3H)-trione : An oxopurine in which the purine ring is substituted by oxo groups at positions 2, 6, and 8.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Among patients with immunoglobulin A nephropathy, the higher levels of fibrinogen and uric acid may mean a higher score of tubular atrophy/interstitial fibrosis, which suggests the renal biopsy should be performed for these patients as early as possible to defined pathological classification, even though there is no obvious abnormal change in the test of renal function." | 8.12 | A high value of fibrinogen in immunoglobulin A nephropathy patients is associated with a worse renal tubular atrophy/interstitial fibrosis score. ( Hu, S; Lou, Z; Tu, M, 2022) |
| "Data on children with IgAN from two pediatric nephrology centers were retrospectively reviewed (renal biopsy - subclasses according Hass I-V, ambulatory blood pressure monitoring ABPM, serum uric acid, proteinuria)." | 7.74 | Ambulatory blood pressure, proteinuria and uric acid in children with IgA nephropathy and their correlation with histopathological findings. ( Dusek, J; Groene, HJ; Janda, J; John, U; Misselwitz, J; Pohl, M; Seeman, T; Stejskal, J; Vondrák, K, 2008) |
| "Renal handling of uric acid and clinical prognosis following episodes of macroscopic hematuria (EMH) were examined in 113 patients with IgA nephropathy (IgAN)." | 7.68 | Evidence of enhanced uric acid clearance in macrohematuric patients with IgA nephropathy: prognostic significance of macrohematuria. ( Miura, M; Nomoto, Y; Sakai, H, 1990) |
| "Serum uric acid (SUA), creatinine clearance (Ccr), urinary excretion of uric acid (UUAV) and uric acid clearance (CUA) were determined in 357 patients with IgA nephritis (IgAN) and 81 patients with membranous nephropathy (MGN) in an attempt to clarify uric acid metabolism in patients with chronic glomerulonephritis, and UUAV/Ccr and CUA/Ccr levels were measured to investigate their correlations." | 7.67 | [Uric acid metabolism in patients with chronic glomerulonephritis]. ( Hosoya, T; Ichida, K; Ikeda, H; Miyahara, T; Sakai, O, 1989) |
| " It has been observed that treatment of hyperuricemia with allopurinol in chronic kidney failure has resulted in a fall in blood pressure and inhibition of the progression of kidney injury." | 4.90 | Aggravation of immunoglobulin a nephropathy by hyperuricemia: a mini-review on current findings and new concepts. ( Baradaran, A; Nasri, H, 2014) |
| "Among patients with immunoglobulin A nephropathy, the higher levels of fibrinogen and uric acid may mean a higher score of tubular atrophy/interstitial fibrosis, which suggests the renal biopsy should be performed for these patients as early as possible to defined pathological classification, even though there is no obvious abnormal change in the test of renal function." | 4.12 | A high value of fibrinogen in immunoglobulin A nephropathy patients is associated with a worse renal tubular atrophy/interstitial fibrosis score. ( Hu, S; Lou, Z; Tu, M, 2022) |
| "Children in the dyslipidemia group had more severe clinical characteristics (higher blood urea nitrogen, serum uric acid, and 24-h proteinuria; higher proportion of hypertension; and lower serum albumin and estimated glomerular filtration rate) and pathological changes (higher proportion of Lee grades IV-V and E1, S1, and C2 in MEST-C)." | 4.12 | Dyslipidemia may be a risk factor for progression in children with IgA nephropathy. ( Chen, L; Jiang, M; Jiang, X; Lin, Z; Xu, Y; Zeng, S; Zhuang, H, 2022) |
| "A total of 86 patients with IgAN and normal renal functions were divided into a hyperuricemia group and a normal serum uric acid group (control group)." | 4.12 | The relationship between serum uric acid levels and glomerular ischemic lesions in patients with Immunoglobin A nephropathy-a analytical cross-sectional study. ( Dai, F; Dong, X; Fang, B; Kang, Y; Qi, L; Wang, Y; Wei, L; Yu, Y, 2022) |
| " The correlations between clinical variables including eGFR, daily proteinuria, mean arterial pressure (MAP), serum uric acid (UA) values, and pathological parameters were examined." | 4.02 | A cross-sectional study in patients with IgA nephropathy of correlations between clinical data and pathological findings at the time of renal biopsy: a Japanese prospective cohort study. ( Hashiguchi, A; Hisano, S; Joh, K; Kamano, C; Katafuchi, R; Kawamura, T; Shimizu, A, 2021) |
| "Plasma uric acid levels indicate tubular interstitial lesions in IgAN and hyperuricemia may be considered as a marker for tubulointerstitial lesions." | 3.80 | Plasma uric acid level indicates tubular interstitial leisions at early stage of IgA nephropathy. ( Chen, Y; Li, X; Liu, Y; Shi, S; Wang, S; Zhang, H; Zhou, J, 2014) |
| "3% of the ones with MN, in 35% of crescentic group, in 42% of FSGS group, in 30% of patients with MPGN and in 33% of the ones with lupus nephritis uric acid levels were found as elevated." | 3.80 | Comparison of laboratory findings in patients with glomerulonephritis classified according to histopathologic diagnosis. ( Bilen, S; Duranay, M; Kirac, Y, 2014) |
| "At the same glomerular filtration rate (GFR), there was no significant difference in the levels of 24 hours proteinuria, blood urea nitrogen (BUN), and serum creatinine between the two groups with different levels of serum uric acid (p > 0." | 3.79 | Clinical and prognostic implications of serum uric acid levels on IgA nephropathy: a cohort study of 348 cases with a mean 5-year follow-up. ( Cheng, GY; Liu, DW; Liu, ZS; Tang, L; Zhang, N; Zhao, ZZ, 2013) |
| "Because approximately 70% of uric acid is excreted from the kidney, hyperuricemia occurs when renal function deteriorates." | 3.77 | Relationship between hyperuricemia and chronic kidney disease. ( Ohno, I, 2011) |
| "Data on children with IgAN from two pediatric nephrology centers were retrospectively reviewed (renal biopsy - subclasses according Hass I-V, ambulatory blood pressure monitoring ABPM, serum uric acid, proteinuria)." | 3.74 | Ambulatory blood pressure, proteinuria and uric acid in children with IgA nephropathy and their correlation with histopathological findings. ( Dusek, J; Groene, HJ; Janda, J; John, U; Misselwitz, J; Pohl, M; Seeman, T; Stejskal, J; Vondrák, K, 2008) |
| "Elevated serum uric acid level is associated with obesity, insulin resistance, diabetes, nephropathy, and hypertension." | 3.74 | Genome scan for determinants of serum uric acid variability. ( Abboud, HE; Arar, NH; Bauer, R; Blangero, J; Comuzzie, AG; Lopez-Alvarenga, JC; MacCluer, JW; Nath, SD; Thameem, F; Voruganti, VS, 2007) |
| "Renal handling of uric acid and clinical prognosis following episodes of macroscopic hematuria (EMH) were examined in 113 patients with IgA nephropathy (IgAN)." | 3.68 | Evidence of enhanced uric acid clearance in macrohematuric patients with IgA nephropathy: prognostic significance of macrohematuria. ( Miura, M; Nomoto, Y; Sakai, H, 1990) |
| "Serum uric acid (SUA), creatinine clearance (Ccr), urinary excretion of uric acid (UUAV) and uric acid clearance (CUA) were determined in 357 patients with IgA nephritis (IgAN) and 81 patients with membranous nephropathy (MGN) in an attempt to clarify uric acid metabolism in patients with chronic glomerulonephritis, and UUAV/Ccr and CUA/Ccr levels were measured to investigate their correlations." | 3.67 | [Uric acid metabolism in patients with chronic glomerulonephritis]. ( Hosoya, T; Ichida, K; Ikeda, H; Miyahara, T; Sakai, O, 1989) |
| "Hyperuricemia has been reported to be correlated with IgA nephropathy (IgAN)." | 2.82 | Is hyperuricemia an independent prognostic factor for IgA nephropathy: a systematic review and meta-analysis of observational cohort studies. ( Cai, Z; Cui, FQ; Jiang, SS; Meng, Y; Tang, L; Wang, MD; Wang, YF; Zhang, K; Zhao, WJ, 2022) |
| " No serious adverse events occurred in any of the 3 groups." | 2.76 | Efficacy and safety of mizoribine combined with losartan in the treatment of IgA nephropathy: a multicenter, randomized, controlled study. ( Chen, P; Chen, X; Huang, S; Li, Y; Lie, C; Liu, S; Miao, L; Wang, L; Wu, X; Xie, Y; Zhang, A, 2011) |
| "The incidence rate of IgA nephropathy complicated with hyperuricaemia was 25." | 1.62 | Association between hyperuricaemia and clinical pathological characteristics of patients with IgA nephropathy. ( Dai, G; Feng, H; Feng, Y; Li, B; Lu, L, 2021) |
| "For retrospective cohort with IgA nephropathy, the patients who received corticosteroid therapy were recruited." | 1.51 | Neutrophil-to-lymphocyte ratio: An effective predictor of corticosteroid response in IgA nephropathy. ( Li, R; Li, Y; Yang, H; Zhang, W, 2019) |
| "Patients with IgA nephropathy with IgG deposition in the glomerular mesangial have severer clinical symptoms and more serious pathological changes." | 1.46 | [Clinical and pathological features in IgA nephropathy with IgG deposition in the glomerular mesangial area]. ( Li, B; Li, JM; Li, YQ; Liu, Q; Shao, XF; Wang, HL; Wang, XH; Xu, XM; Zhang, Y; Zhu, SS; Zou, HQ, 2017) |
| "Fifty ESRD patients with the primary cause of IgAN and a short renal survival time of less than ten years after diagnose were enrolled in the case group." | 1.46 | Risk factors of progressive IgA nephropathy which progress to end stage renal disease within ten years: a case-control study. ( Chen, C; Ding, X; Huang, P; Lin, H; Lv, Y; Shu, D; Su, Z; Xu, F; Zhang, J, 2017) |
| "IgA nephropathy with chronic renal failure usually occurred in young adults, and it had severe clinical condition and pathological changes, while there was no significant relationship between them." | 1.43 | Clinical and pathological analysis of IgA nephropathy with chronic renal failure. ( Chai, H; Hu, Q; Liu, Y; Shen, P; Tang, L; Yuan, G; Zhou, Y, 2016) |
| "A total of 127 IgA nephropathy patients with microalbuminuria were followed up successfully, with an average follow-up of (49." | 1.43 | [Clinico-pathological characteristics and prognosis of IgA nephropathy patients with microalbuminuria and deposition of complement C3]. ( Du, XY; Guo, ZY; Li, X; Wang, YY; Wu, YM; Xu, Y; Zhang, W; Zhou, SG, 2016) |
| "High uric acid level is a known risk factor for deterioration of renal function in chronic kidney disease (CKD), but its influence on the progression of IgA nephropathy (IgAN) remains unclear." | 1.42 | High uric acid level is a risk factor for progression of IgA nephropathy with chronic kidney disease stage G3a. ( Itabashi, M; Iwabuchi, Y; Kataoka, H; Moriyama, T; Nishida, M; Nitta, K; Sato, M; Shimizu, A; Takei, T; Uchida, K, 2015) |
| "Uric acid-lowering treatments may be beneficial for the prevention of progression of IgAN." | 1.42 | Hyperuricemia is associated with progression of IgA nephropathy. ( Bakan, A; Basci, S; Covic, A; Elcioglu, OC; Kanbay, M; Kostek, O; Oral, A; Ozkok, A; Ozturk, S; Sipahioglu, M; Sumnu, A; Takir, M; Turkmen, A; Voroneanu, L, 2015) |
| "Subjects with IgA nephropathy could be separated into those who showed a fall in EPO levels (n = 24) and those who showed no change or a rise in EPO levels (n = 22)." | 1.42 | Dopamine-Induced Changes in Serum Erythropoietin and Creatinine Clearance Reflect Risk Factors for Progression of IgA Nephropathy. ( Johnson, RJ; Korenkiewicz, J; Manitius, J; Marszalek, A; Odrowaz-Sypniewska, G; Sulikowska, B; Wiechecka-Korenkiewicz, J, 2015) |
| "Totally 148 patients diagnosed as IgA nephropathy by renal biopsy in our hospital from January 2007 to December 2010 were divided into hyperuricaemic group (41 cases) and non-hyperuricaemic group (107 cases) according to the level of serum uric acid." | 1.37 | [The relationship between hyperuricaemia and clinic pathology of IgA nephropathy]. ( Cui, MJ; Wang, HY; Xiao, QF; Zhang, BH; Zhu, FL, 2011) |
| "Patients with IgA nephropathy versus controls: DIR 8." | 1.35 | Uric acid excretion and dopamine-induced glomerular filtration response in patients with IgA glomerulonephritis. ( Manitius, J; Odrowaz-Sypniewska, G; Rutkowski, B; Sulikowska, B; Łysiak-Szydłowska, W, 2008) |
| "The prognosis of IgA nephropathy (IgAN) is variable and about 10-20% of patients progress to end-stage renal disease (ESRD) in 10 years." | 1.31 | Hypertriglyceridaemia and hyperuricaemia are risk factors for progression of IgA nephropathy. ( Mustonen, J; Pasternack, A; Syrjänen, J, 2000) |
| "Hyperuricemia in IgA nephropathy is derived from both glomerular and tubulointerstitial damage, and correlated with hypertension." | 1.31 | Serum uric acid and renal prognosis in patients with IgA nephropathy. ( Gomi, H; Hikita, M; Hosoya, T; Ichida, K; Ohno, I; Okabe, H, 2001) |
| "We report a case of IgA nephropathy associated with renal hypouricemia." | 1.29 | [A case of renal hypouricemia associated with IgA nephropathy--with special reference to changes in serum uric acid and uric acid clearance in a clinical course exceeding 15 years]. ( Koni, I; Nakashima, A; Tofuku, Y, 1994) |
| "Twenty-eight patients with IgA nephropathy were examined." | 1.28 | Serum levels of interleukin-2 receptor and disease activity in patients with IgA nephropathy. ( Ito, K; Koide, H; Ozaki, T; Takahashi, M; Tomino, Y, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (3.57) | 18.7374 |
| 1990's | 4 (7.14) | 18.2507 |
| 2000's | 8 (14.29) | 29.6817 |
| 2010's | 28 (50.00) | 24.3611 |
| 2020's | 14 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tu, M | 1 |
| Hu, S | 1 |
| Lou, Z | 1 |
| Zhang, K | 1 |
| Tang, L | 3 |
| Jiang, SS | 1 |
| Wang, YF | 1 |
| Meng, Y | 1 |
| Wang, MD | 1 |
| Cui, FQ | 1 |
| Cai, Z | 1 |
| Zhao, WJ | 1 |
| Wei, H | 1 |
| Chen, L | 2 |
| Li, Q | 2 |
| Liang, X | 1 |
| Wang, K | 1 |
| Zhang, Y | 2 |
| Li, Y | 3 |
| Liu, Y | 5 |
| Xu, G | 1 |
| Zhuang, H | 1 |
| Lin, Z | 1 |
| Zeng, S | 1 |
| Jiang, M | 1 |
| Jiang, X | 1 |
| Xu, Y | 2 |
| Li, H | 1 |
| Wang, F | 1 |
| Jia, J | 1 |
| Yan, T | 1 |
| Lin, S | 1 |
| Fang, B | 1 |
| Yu, Y | 1 |
| Dong, X | 1 |
| Qi, L | 1 |
| Wang, Y | 1 |
| Dai, F | 1 |
| Wei, L | 1 |
| Kang, Y | 1 |
| Huang, Z | 1 |
| Hu, Y | 1 |
| Chen, B | 1 |
| Liang, Y | 1 |
| Li, D | 2 |
| Qiu, W | 1 |
| Zhang, J | 6 |
| Chen, C | 3 |
| Han, X | 1 |
| Xiao, Y | 1 |
| Tang, Y | 1 |
| Zheng, X | 1 |
| Anwar, M | 1 |
| Qin, W | 1 |
| Enya, T | 1 |
| Miyazaki, K | 1 |
| Miyazawa, T | 1 |
| Oshima, R | 1 |
| Morimoto, Y | 1 |
| Okada, M | 1 |
| Takemura, T | 1 |
| Sugimoto, K | 1 |
| Wei, W | 1 |
| Yu, C | 1 |
| Xing, L | 1 |
| Wang, M | 1 |
| Liu, R | 1 |
| Ma, J | 2 |
| Liu, X | 2 |
| Xie, R | 1 |
| Sui, M | 1 |
| Russo, E | 1 |
| Drovandi, S | 1 |
| Salvidio, G | 1 |
| Verzola, D | 1 |
| Esposito, P | 1 |
| Garibotto, G | 1 |
| Viazzi, F | 1 |
| Liu, H | 1 |
| Peng, L | 1 |
| He, L | 1 |
| Long, K | 1 |
| Ouyang, X | 1 |
| Wu, C | 1 |
| Xie, M | 1 |
| Dai, L | 1 |
| Cai, X | 1 |
| Kamano, C | 1 |
| Shimizu, A | 2 |
| Joh, K | 1 |
| Hashiguchi, A | 1 |
| Hisano, S | 1 |
| Katafuchi, R | 2 |
| Kawamura, T | 1 |
| Hogg, R | 1 |
| Lu, L | 1 |
| Li, B | 3 |
| Dai, G | 1 |
| Feng, Y | 1 |
| Feng, H | 1 |
| Xu, XM | 1 |
| Zhu, SS | 1 |
| Wang, XH | 1 |
| Shao, XF | 1 |
| Liu, Q | 1 |
| Li, JM | 1 |
| Wang, HL | 1 |
| Li, YQ | 1 |
| Zou, HQ | 1 |
| Zhou, S | 1 |
| Fu, J | 1 |
| Liu, M | 1 |
| Yang, S | 1 |
| Zhou, Q | 3 |
| Yu, X | 2 |
| Yang, Q | 2 |
| Pan, M | 1 |
| Zheng, S | 1 |
| You, X | 1 |
| Xu, F | 2 |
| Li, Z | 1 |
| Zhou, Z | 1 |
| Zhu, B | 1 |
| Yu, DR | 1 |
| Lv, JC | 1 |
| Lin, Y | 1 |
| Yin, JZ | 1 |
| Du, YY | 1 |
| Tang, XL | 1 |
| Mao, LC | 1 |
| Li, QF | 1 |
| Sun, Y | 1 |
| Liu, L | 1 |
| Li, XF | 1 |
| Fei, D | 1 |
| Wei, XY | 1 |
| Zhu, CF | 1 |
| Cheng, XX | 1 |
| Chen, HY | 1 |
| Wang, YJ | 1 |
| Fan, P | 1 |
| Song, J | 1 |
| Chen, Q | 1 |
| Cheng, X | 1 |
| Zou, C | 1 |
| Xie, B | 1 |
| Yang, H | 1 |
| Zhang, W | 3 |
| Li, R | 1 |
| Zhou, J | 1 |
| Chen, Y | 1 |
| Shi, S | 1 |
| Li, X | 2 |
| Wang, S | 1 |
| Zhang, H | 2 |
| Kirac, Y | 1 |
| Bilen, S | 1 |
| Duranay, M | 1 |
| Nasri, H | 1 |
| Baradaran, A | 1 |
| Moriyama, T | 2 |
| Itabashi, M | 1 |
| Takei, T | 1 |
| Kataoka, H | 1 |
| Sato, M | 1 |
| Iwabuchi, Y | 1 |
| Nishida, M | 1 |
| Uchida, K | 1 |
| Nitta, K | 1 |
| Bakan, A | 1 |
| Oral, A | 1 |
| Elcioglu, OC | 1 |
| Takir, M | 1 |
| Kostek, O | 1 |
| Ozkok, A | 1 |
| Basci, S | 1 |
| Sumnu, A | 1 |
| Ozturk, S | 1 |
| Sipahioglu, M | 1 |
| Turkmen, A | 1 |
| Voroneanu, L | 1 |
| Covic, A | 1 |
| Kanbay, M | 1 |
| Sulikowska, B | 3 |
| Johnson, RJ | 2 |
| Wiechecka-Korenkiewicz, J | 1 |
| Korenkiewicz, J | 1 |
| Marszalek, A | 1 |
| Odrowaz-Sypniewska, G | 3 |
| Manitius, J | 3 |
| Lin, L | 1 |
| Yang, J | 2 |
| Li, K | 1 |
| Huo, B | 1 |
| Dai, H | 1 |
| Tan, W | 1 |
| He, Y | 1 |
| Fu, QY | 1 |
| Ma, L | 2 |
| Li, CC | 1 |
| He, FG | 1 |
| He, ZJ | 1 |
| Zhang, WS | 1 |
| Zhang, ZH | 1 |
| Caliskan, Y | 1 |
| Ozluk, Y | 1 |
| Celik, D | 1 |
| Oztop, N | 1 |
| Aksoy, A | 1 |
| Ucar, AS | 1 |
| Yazici, H | 1 |
| Kilicaslan, I | 1 |
| Sever, MS | 1 |
| Guo, ZY | 1 |
| Zhou, SG | 1 |
| Wang, YY | 1 |
| Du, XY | 1 |
| Wu, YM | 1 |
| Ai, Z | 1 |
| Xu, R | 1 |
| Liu, W | 1 |
| Huang, F | 1 |
| Wu, J | 1 |
| Duan, SW | 1 |
| Sun, XF | 1 |
| Li, WG | 1 |
| Wang, YP | 1 |
| Liu, WH | 1 |
| Zhang, JR | 1 |
| Lun, LD | 1 |
| Li, XM | 1 |
| Zhou, CH | 1 |
| Li, JJ | 1 |
| Liu, SW | 1 |
| Xie, YS | 1 |
| Cai, GY | 1 |
| Huang, W | 1 |
| Wu, H | 1 |
| Jia, Q | 1 |
| Chen, XM | 1 |
| Hu, Q | 1 |
| Shen, P | 1 |
| Yuan, G | 1 |
| Zhou, Y | 1 |
| Chai, H | 1 |
| Nagasawa, Y | 1 |
| Yamamoto, R | 1 |
| Shoji, T | 1 |
| Shinzawa, M | 1 |
| Hasuike, Y | 1 |
| Nagatoya, K | 1 |
| Yamauchi, A | 1 |
| Hayashi, T | 1 |
| Kuragano, T | 1 |
| Isaka, Y | 1 |
| Nakanishi, T | 1 |
| Matsukuma, Y | 1 |
| Masutani, K | 1 |
| Tanaka, S | 1 |
| Tsuchimoto, A | 1 |
| Fujisaki, K | 1 |
| Torisu, K | 1 |
| Hirakata, H | 1 |
| Tsuruya, K | 1 |
| Kitazono, T | 1 |
| Shu, D | 1 |
| Su, Z | 1 |
| Ding, X | 1 |
| Lv, Y | 1 |
| Lin, H | 1 |
| Huang, P | 1 |
| Seeman, T | 1 |
| Pohl, M | 1 |
| John, U | 1 |
| Dusek, J | 1 |
| Vondrák, K | 1 |
| Janda, J | 1 |
| Stejskal, J | 1 |
| Groene, HJ | 1 |
| Misselwitz, J | 1 |
| Xie, Y | 1 |
| Huang, S | 1 |
| Wang, L | 2 |
| Miao, L | 1 |
| Zhang, A | 1 |
| Wu, X | 1 |
| Liu, S | 1 |
| Lie, C | 1 |
| Chen, P | 1 |
| Chen, X | 1 |
| Cui, MJ | 1 |
| Zhang, BH | 1 |
| Xiao, QF | 1 |
| Zhu, FL | 1 |
| Wang, HY | 1 |
| Ohno, I | 2 |
| Cheng, GY | 1 |
| Liu, DW | 1 |
| Zhang, N | 1 |
| Zhao, ZZ | 1 |
| Liu, ZS | 1 |
| Myllymäki, J | 1 |
| Honkanen, T | 1 |
| Syrjänen, J | 2 |
| Helin, H | 1 |
| Rantala, I | 1 |
| Pasternack, A | 2 |
| Mustonen, J | 2 |
| de Groot, K | 1 |
| Nath, SD | 1 |
| Voruganti, VS | 1 |
| Arar, NH | 1 |
| Thameem, F | 1 |
| Lopez-Alvarenga, JC | 1 |
| Bauer, R | 1 |
| Blangero, J | 1 |
| MacCluer, JW | 1 |
| Comuzzie, AG | 1 |
| Abboud, HE | 1 |
| Łysiak-Szydłowska, W | 1 |
| Rutkowski, B | 1 |
| Tofuku, Y | 1 |
| Nakashima, A | 1 |
| Koni, I | 1 |
| Konopielko, Z | 1 |
| Zawadzki, J | 1 |
| Wyszyńska, T | 1 |
| Treviño-Becerra, A | 1 |
| Hosoya, T | 2 |
| Gomi, H | 1 |
| Ichida, K | 2 |
| Okabe, H | 1 |
| Hikita, M | 1 |
| Panasiuk, NN | 1 |
| Mukhin, NA | 1 |
| Varshavskiĭ, VA | 1 |
| Maksimov, NA | 1 |
| Nikolaev, AIu | 1 |
| Poliantseva, LR | 1 |
| Balkarov, IM | 1 |
| Golov, KG | 1 |
| Antonov, MV | 1 |
| Aleksandrovskaia, TN | 1 |
| Miura, M | 1 |
| Nomoto, Y | 1 |
| Sakai, H | 1 |
| Tomino, Y | 1 |
| Ozaki, T | 1 |
| Koide, H | 1 |
| Takahashi, M | 1 |
| Ito, K | 1 |
| Ikeda, H | 1 |
| Sakai, O | 1 |
| Miyahara, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Value of Uric Acid as Early Predictor of Lupus Nephritis in Assiut University Hospital[NCT05402735] | 100 participants (Anticipated) | Observational | 2022-06-15 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for uric acid and Berger Disease
| Article | Year |
|---|---|
Is hyperuricemia an independent prognostic factor for IgA nephropathy: a systematic review and meta-analysis of observational cohort studies.
Topics: Cohort Studies; Glomerulonephritis, IGA; Humans; Hyperuricemia; Observational Studies as Topic; Prog | 2022 |
An evaluation of the roles of hematuria and uric acid in defining the prognosis of patients with IgA nephropathy.
Topics: Female; Glomerulonephritis, IGA; Hematuria; Humans; Kidney; Male; Prognosis; Uric Acid | 2022 |
Aggravation of immunoglobulin a nephropathy by hyperuricemia: a mini-review on current findings and new concepts.
Topics: Allopurinol; Disease Progression; Glomerulonephritis, IGA; Gout Suppressants; Humans; Hyperuricemia; | 2014 |
2 trials available for uric acid and Berger Disease
| Article | Year |
|---|---|
Efficacy of Leflunomide, Telmisartan, and Clopidogrel for Immunoglobulin A Nephropathy: A Randomized Controlled Trial.
Topics: Adolescent; Adult; Benzimidazoles; Benzoates; Blood Pressure; China; Clopidogrel; Creatinine; Female | 2016 |
Efficacy and safety of mizoribine combined with losartan in the treatment of IgA nephropathy: a multicenter, randomized, controlled study.
Topics: Adult; Angiotensin Receptor Antagonists; Blood Pressure; China; Creatinine; Drug Synergism; Drug The | 2011 |
51 other studies available for uric acid and Berger Disease
| Article | Year |
|---|---|
A high value of fibrinogen in immunoglobulin A nephropathy patients is associated with a worse renal tubular atrophy/interstitial fibrosis score.
Topics: Adult; Atrophy; Female; Fibrinogen; Fibrosis; Glomerulonephritis, IGA; Humans; Kidney Tubules; Male; | 2022 |
CD137L-macrophage induce lymphatic endothelial cells autophagy to promote lymphangiogenesis in renal fibrosis.
Topics: 4-1BB Ligand; Animals; Autophagy; Endothelial Cells; Female; Fibrosis; Glomerulonephritis, IGA; Huma | 2022 |
Dyslipidemia may be a risk factor for progression in children with IgA nephropathy.
Topics: Child; Disease Progression; Dyslipidemias; Glomerular Filtration Rate; Glomerulonephritis, IGA; Huma | 2022 |
The difference between patients with nephrotic syndrome and nephrotic-range proteinuria in IgA nephropathy: a propensity score matched cohort study.
Topics: Adult; Cohort Studies; Creatinine; Female; Glomerulonephritis, IGA; Humans; Male; Nephrotic Syndrome | 2022 |
The relationship between serum uric acid levels and glomerular ischemic lesions in patients with Immunoglobin A nephropathy-a analytical cross-sectional study.
Topics: Cross-Sectional Studies; Glomerulonephritis, IGA; Humans; Hyperuricemia; Retrospective Studies; Uric | 2022 |
Clinical significance of intrarenal vascular lesions in non-hypertensive patients with IgA nephropathy.
Topics: Clinical Relevance; Disease Progression; Glomerular Filtration Rate; Glomerulonephritis, IGA; Humans | 2023 |
Clinical and pathological features of immunoglobulin A nephropathy patients with nephrotic syndrome.
Topics: Adult; China; Creatine; Disease Progression; Female; Glomerular Filtration Rate; Glomerulonephritis, | 2019 |
Early tonsillectomy for severe immunoglobulin A nephropathy significantly reduces proteinuria.
Topics: Adolescent; Child; Child, Preschool; Combined Modality Therapy; Creatinine; Female; Glomerulonephrit | 2020 |
Epidemiology and risk factors for progression in Chinese patients with IgA nephropathy.
Topics: China; Glomerulonephritis, IGA; Humans; Kidney; Male; Retrospective Studies; Risk Factors; Uric Acid | 2021 |
Increased serum uric acid levels are associated to renal arteriolopathy and predict poor outcome in IgA nephropathy.
Topics: Adult; Aged; Arterioles; Biomarkers; Biopsy; Disease Progression; Female; Glomerulonephritis, IGA; H | 2020 |
Low expression of estrogen receptor β in renal tubular epithelial cells may cause hyperuricemia in premenopausal patients with systemic lupus erythematosus.
Topics: Adult; Biopsy; Case-Control Studies; Creatinine; Epithelial Cells; Estrogen Receptor beta; Female; G | 2021 |
A cross-sectional study in patients with IgA nephropathy of correlations between clinical data and pathological findings at the time of renal biopsy: a Japanese prospective cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arterial Pressure; Biopsy; Child; Child, Preschool; Cros | 2021 |
Association between hyperuricaemia and clinical pathological characteristics of patients with IgA nephropathy.
Topics: Creatinine; Glomerulonephritis, IGA; Humans; Hyperuricemia; Kidney; Uric Acid | 2021 |
[Clinical and pathological features in IgA nephropathy with IgG deposition in the glomerular mesangial area].
Topics: Creatinine; Glomerular Filtration Rate; Glomerular Mesangium; Glomerulonephritis, IGA; Humans; Immun | 2017 |
The prevalence and risk factors of abnormal circadian blood pressure in patients with IgA nephropathy
.
Topics: Adult; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadian Rhythm; Female; Glomerular F | 2017 |
Serum C3/C4 ratio is a novel predictor of renal prognosis in patients with IgA nephropathy: a retrospective study.
Topics: Adult; Complement C3; Complement C4; Creatinine; Female; Glomerular Filtration Rate; Glomerulonephri | 2018 |
Uric Acid as a Predictor of Immunoglobulin A Nephropathy Progression: A Cohort Study of 1965 Cases.
Topics: Adult; Disease Progression; Female; Follow-Up Studies; Glomerular Filtration Rate; Glomerulonephriti | 2018 |
The influence of environmental factors on clinical pathological changes of patients with immunoglobulin A nephropathy from different areas of China.
Topics: Adult; Case-Control Studies; China; Cholesterol; Complement C3; Creatinine; Environment; Female; Glo | 2018 |
Neutrophil-to-lymphocyte ratio: An effective predictor of corticosteroid response in IgA nephropathy.
Topics: Adrenal Cortex Hormones; Adult; Creatinine; Female; Glomerular Filtration Rate; Glomerulonephritis, | 2019 |
Plasma uric acid level indicates tubular interstitial leisions at early stage of IgA nephropathy.
Topics: Adult; Biomarkers; Early Diagnosis; Female; Glomerulonephritis, IGA; Humans; Hyperuricemia; Male; Ne | 2014 |
Comparison of laboratory findings in patients with glomerulonephritis classified according to histopathologic diagnosis.
Topics: Analysis of Variance; Biopsy; C-Reactive Protein; Complement C3; Complement C4; Female; Glomerulonep | 2014 |
High uric acid level is a risk factor for progression of IgA nephropathy with chronic kidney disease stage G3a.
Topics: Biomarkers; Biopsy; Chi-Square Distribution; Disease Progression; Female; Glomerulonephritis, IGA; H | 2015 |
Hyperuricemia is associated with progression of IgA nephropathy.
Topics: Adult; Biomarkers; Disease Progression; Female; Follow-Up Studies; Glomerular Filtration Rate; Glome | 2015 |
Dopamine-Induced Changes in Serum Erythropoietin and Creatinine Clearance Reflect Risk Factors for Progression of IgA Nephropathy.
Topics: Adult; Case-Control Studies; Creatinine; Disease Progression; Dopamine; Erythropoietin; Female; Glom | 2015 |
Nocturnal and Circadian Rhythm of Blood Pressure Is Associated with Renal Structure Damage and Function in Patients with IgAN.
Topics: Adolescent; Adult; Aorta, Thoracic; Asian People; Blood Pressure; Blood Pressure Monitoring, Ambulat | 2016 |
Clinical Characteristics and Renal Histology in Pediatric Patients with Hypertension and Prehypertension Secondary to IgA Nephropathy.
Topics: Adolescent; Age Factors; Blood Pressure; Child; Child, Preschool; Female; Glomerular Filtration Rate | 2016 |
The Clinical Significance of Uric Acid and Complement Activation in the Progression of IgA Nephropathy.
Topics: Adolescent; Adult; Aged; Biomarkers; Complement Activation; Complement C3; Disease Progression; Fema | 2016 |
[Clinico-pathological characteristics and prognosis of IgA nephropathy patients with microalbuminuria and deposition of complement C3].
Topics: Albuminuria; Complement C3; Creatinine; Glomerulonephritis, IGA; Humans; Immunoglobulin A; Kaplan-Me | 2016 |
Clinicopathologic features of IgA nephropathy patients with different levels of proteinuria.
Topics: Adult; Atrophy; Biopsy; Female; Fibrosis; Glomerular Filtration Rate; Glomerulonephritis, IGA; Glome | 2016 |
Clinical and pathological analysis of IgA nephropathy with chronic renal failure.
Topics: Adult; Biopsy; Blood Pressure; Blood Urea Nitrogen; Creatinine; Disease Progression; Female; Follow- | 2016 |
Serum Uric Acid Level Predicts Progression of IgA Nephropathy in Females but Not in Males.
Topics: Adult; Disease Progression; Female; Glomerulonephritis, IGA; Humans; Hyperuricemia; Male; Middle Age | 2016 |
A J-shaped association between serum uric acid levels and poor renal survival in female patients with IgA nephropathy.
Topics: Adult; Disease Progression; Female; Glomerulonephritis, IGA; Humans; Kidney; Kidney Failure, Chronic | 2017 |
Risk factors of progressive IgA nephropathy which progress to end stage renal disease within ten years: a case-control study.
Topics: Adult; Case-Control Studies; Cholesterol; Disease Progression; Female; Glomerular Filtration Rate; G | 2017 |
Ambulatory blood pressure, proteinuria and uric acid in children with IgA nephropathy and their correlation with histopathological findings.
Topics: Adolescent; Blood Pressure Monitoring, Ambulatory; Child; Circadian Rhythm; Diastole; Female; Glomer | 2008 |
[The relationship between hyperuricaemia and clinic pathology of IgA nephropathy].
Topics: Adult; Arterioles; Female; Glomerulonephritis, IGA; Humans; Hyperuricemia; Male; Middle Aged; Renal | 2011 |
Uric acid, renal vasoconstriction and erythropoietin relationship in IgA nephropathy revealed by dopamine-induced glomerular filtration response.
Topics: Adult; Biomarkers; Dopamine; Erythropoietin; Female; Glomerular Filtration Rate; Glomerulonephritis, | 2012 |
Relationship between hyperuricemia and chronic kidney disease.
Topics: Glomerulonephritis, IGA; Humans; Hypertension; Hyperuricemia; Kidney; Kidney Failure, Chronic; Kidne | 2011 |
Clinical and prognostic implications of serum uric acid levels on IgA nephropathy: a cohort study of 348 cases with a mean 5-year follow-up.
Topics: Adult; Blood Urea Nitrogen; Confidence Intervals; Creatinine; Follow-Up Studies; Glomerular Filtrati | 2013 |
Uric acid correlates with the severity of histopathological parameters in IgA nephropathy.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Biomarkers; Biopsy, Needle; Cohort Studies; Disease P | 2005 |
[Renal manifestations in rheumatic diseases].
Topics: Amyloidosis; Diagnosis, Differential; Glomerulonephritis, IGA; Glomerulonephritis, Membranoprolifera | 2007 |
Genome scan for determinants of serum uric acid variability.
Topics: Adult; Blood Pressure; Cardiovascular Diseases; Chromosome Mapping; Diabetes Mellitus, Type 2; Femal | 2007 |
Uric acid excretion and dopamine-induced glomerular filtration response in patients with IgA glomerulonephritis.
Topics: Acetylglucosaminidase; Adolescent; Adult; Case-Control Studies; Dopamine; Female; Glomerular Filtrat | 2008 |
[A case of renal hypouricemia associated with IgA nephropathy--with special reference to changes in serum uric acid and uric acid clearance in a clinical course exceeding 15 years].
Topics: Creatinine; Female; Follow-Up Studies; Glomerulonephritis, IGA; Humans; Kidney Tubules; Middle Aged; | 1994 |
[Uric acid metabolism abnormalities in IgA nephropathies].
Topics: Abdominal Pain; Adolescent; Calculi; Child; Child, Preschool; Creatinine; Glomerulonephritis, IGA; H | 1996 |
Hypertriglyceridaemia and hyperuricaemia are risk factors for progression of IgA nephropathy.
Topics: Adolescent; Adult; Aged; Child; Female; Glomerulonephritis, IGA; Humans; Hypercholesterolemia; Hyper | 2000 |
Hypertriglyceridaemia and hyperuricaemia in IgA nephropathy.
Topics: Glomerulonephritis, IGA; Humans; Hypertriglyceridemia; Middle Aged; Uric Acid | 2001 |
Serum uric acid and renal prognosis in patients with IgA nephropathy.
Topics: Adult; Biomarkers; Biopsy; Creatinine; Female; Glomerulonephritis, IGA; Humans; Kidney; Male; Progno | 2001 |
[The clinico-morphological characteristics of psoriatic nephropathy].
Topics: Adolescent; Adult; Aged; Amyloidosis; Arthritis, Psoriatic; Chronic Disease; Female; Glomerulonephri | 1990 |
Evidence of enhanced uric acid clearance in macrohematuric patients with IgA nephropathy: prognostic significance of macrohematuria.
Topics: Adult; Atrophy; Female; Follow-Up Studies; Glomerulonephritis, IGA; Hematuria; Humans; Kidney Functi | 1990 |
Serum levels of interleukin-2 receptor and disease activity in patients with IgA nephropathy.
Topics: Adult; Blood Urea Nitrogen; Enzyme-Linked Immunosorbent Assay; Female; Fluorescent Antibody Techniqu | 1989 |
[Uric acid metabolism in patients with chronic glomerulonephritis].
Topics: Adult; Chronic Disease; Female; Glomerulonephritis; Glomerulonephritis, IGA; Glomerulonephritis, Mem | 1989 |